Phase 1 Study of EZN-2968 Weekly in Adult Patients With Advanced Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, non-randomized, dose-escalation study to determine the maximum
tolerated dose (MTD), safety, tolerance, and pharmacologic profile of EZN-2968, a locked
nucleic acid antisense oligonucleotide against hypoxia-inducible factor 1α administered as a
2-hour intravenous (i.v.) infusion weekly for 3 weeks per 6-week cycle. In patients treated
at a recommended Phase 2 dose of EZN-2968, dose intensification will proceed by maintaining
the dose, but gradually increasing the number of doses per 6-week cycle. Up to 3
intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.